- Home
- NGS vs GOSS Comparison
NGS vs GOSS Comparison
Compare NGS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- GOSS
- Stock Information
- Founded
- NGS 1998
- GOSS 2015
- Country
- NGS United States
- GOSS United States
- Employees
- NGS N/A
- GOSS N/A
- Industry
- NGS Oilfield Services/Equipment
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NGS Energy
- GOSS Health Care
- Exchange
- NGS Nasdaq
- GOSS Nasdaq
- Market Cap
- NGS 304.4M
- GOSS 347.8M
- IPO Year
- NGS 2002
- GOSS 2019
- Fundamental
- Price
- NGS $24.32
- GOSS $2.16
- Analyst Decision
- NGS Strong Buy
- GOSS Strong Buy
- Analyst Count
- NGS 2
- GOSS 4
- Target Price
- NGS $32.50
- GOSS $8.25
- AVG Volume (30 Days)
- NGS 50.5K
- GOSS 3.2M
- Earning Date
- NGS 08-11-2025
- GOSS 08-05-2025
- Dividend Yield
- NGS N/A
- GOSS N/A
- EPS Growth
- NGS 76.16
- GOSS N/A
- EPS
- NGS 1.34
- GOSS N/A
- Revenue
- NGS $161,218,000.00
- GOSS $124,590,000.00
- Revenue This Year
- NGS $13.56
- GOSS N/A
- Revenue Next Year
- NGS $15.42
- GOSS $63.97
- P/E Ratio
- NGS $18.12
- GOSS N/A
- Revenue Growth
- NGS 22.64
- GOSS N/A
- 52 Week Low
- NGS $16.70
- GOSS $0.66
- 52 Week High
- NGS $29.74
- GOSS $2.23
- Technical
- Relative Strength Index (RSI)
- NGS 48.57
- GOSS 74.29
- Support Level
- NGS $22.72
- GOSS $1.91
- Resistance Level
- NGS $24.84
- GOSS $2.18
- Average True Range (ATR)
- NGS 0.77
- GOSS 0.17
- MACD
- NGS -0.02
- GOSS 0.03
- Stochastic Oscillator
- NGS 66.39
- GOSS 88.24
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.